Skip to main content

Advertisement

SpringerLink
Log in

The safety and use of short-acting nifedipine in hospitalized hypertensive children

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Recent reports suggest that calcium channel blockers are harmful in the treatment of acute hypertension in adults. However, short-acting nifedipine is an effective and useful medication in pediatric hypertension and is currently utilized for hypertensive emergencies. This study will address these safety concerns in hypertensive children. Medical records (from five Canadian pediatric hospitals) of all pediatric hypertensive hospitalized children who were treated with short-acting nifedipine from January 1995 to December 1998 were retrospectively reviewed for patient demographics, dosing regimen, use of concomitant medications, co-morbid conditions, and presence/absence of minor and serious adverse events. Final data were extracted from 182 patients. Each patient had an average of 2.6 episodes of hypertension in hospital that required treatment, totaling 477 episodes. Within the 477 episodes, 1,162 doses of short-acting nifedipine were administered. The mean dose was 0.22 mg/kg (range 0.043–0.67 mg/kg, median 0.19 mg/kg) with 55.6% (260/468 episodes) receiving the drug via the sublingual route. Hypertension resolved in 85.5% (408/477) of the episodes. There were only 29 of 574 (5.1%) minor adverse events that were definitely or probably related to short-acting nifedipine administration. Two patients experienced a serious adverse event that involved of a reduction in blood pressure of more than 40%, but neither had any symptomatology from the serious adverse event and recovered spontaneously within 2 h. Short-acting nifedipine in hypertensive, hospitalized children appears to be a safe and efficacious medication with minimal side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Psaty BM, Heckbert SR, Koepsall TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, et al (1995) The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 274:620–625

    CAS  PubMed  Google Scholar 

  2. Furberg CD, Psaty BM, Meyer JV (1995) Nifedipine—dose-related increase in mortality in patients with coronary artery disease. Circulation 92:1326–1331

    CAS  PubMed  Google Scholar 

  3. Mahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ (1995) Long-term survival and use of anti-hypertensive medications in older persons. J Am Geriatr Soc 43:1191–1197

    PubMed  Google Scholar 

  4. Cutler JA (1998) Calcium-channel blockers for hypertension—uncertainty continues. N Engl J Med 338:679–681

    Article  CAS  PubMed  Google Scholar 

  5. Yusuf S, Held P, Furberg C (1991) Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 67:1295–1297

    CAS  PubMed  Google Scholar 

  6. Health Protection Branch (1996) Safety of calcium-channel blockers in the treatment of patients with hypertension and coronary artery disease. Health Canada DD no.44

  7. Barnett AA (1996) FDA committee rules calcium channel blockers safe. Lancet 347:313

    Article  Google Scholar 

  8. Marwick C (1996) FDA gives calcium channel blockers clean bill of health but warns against the use of short-acting nifedipine hazards. JAMA 275:423–434

    Article  CAS  PubMed  Google Scholar 

  9. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthe Floras JS, Haynes RB, Honos G, Leenen FH, Leiter LA, Logan AG, My MG, Spence JD, Zarnke KB (1999) 1999 Canadian recommendations for the management of hypertension. Can Med Assoc J 12 [Suppl]:161

  10. Millar JA (1997) Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy. Med J Aust 166:640–643

    PubMed  Google Scholar 

  11. Anonymous (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics 98:649–658

    PubMed  Google Scholar 

  12. Sinaiko AR (1996) Hypertension in children. N Engl J Med 335:1968–1973

    Google Scholar 

  13. Gauthier B, Trachtman H (1997) Short-acting nifedipine. Pediatr Nephrol 11:786–787

    CAS  PubMed  Google Scholar 

  14. Calvette A, Martino S. von Vigier RO, Schmidtko J, Fossali E, Bianchetti MG (2002) “What goes up must immediately come down!” Which indication for short-acting nifedipine in children with arterial hypertension. Pediatr Nephrol 18:1–2

    PubMed  Google Scholar 

  15. Flynn JT (2002) Nifedipine in the treatment of hypertension in children. J Pediatr 140:787–788

    Article  Google Scholar 

  16. Blaszak RT, Savage JA, Ellis EN (2001) The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 139:7–9

    CAS  PubMed  Google Scholar 

  17. Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S (2002) Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 17:35–40

    PubMed  Google Scholar 

  18. Evans JHC, Shaw NJ, Brocklebank JT (1988) Sublingual nifedipine in acute severe hypertension. Arch Dis Child 63:975–977

    CAS  PubMed  Google Scholar 

  19. Rubenstein EB, Escalante C (1989) Hypertensive crisis. Crit Care Clin 5:477–495

    CAS  PubMed  Google Scholar 

  20. Sanchez BM, Estepa Soto MR, Lopez Verde L, Benito A, Hernand Lorca MA, Garcia Santiago M, Zancada B (1984) Normal blood pressure values in Spanish children. An Esp Pediatr 20:1–7

    PubMed  Google Scholar 

  21. Dilmen U, Çaglar MK, Senses A, Kinik E (1983) Nifedipine in hypertensive emergencies of children. Am J Dis Child 137:1162–1165

    PubMed  Google Scholar 

  22. Siegler R, Brewer E (1988) Effect of sublingual or oral nifedipine in the treatment of hypertension. J Pediatr 112:811–813

    CAS  PubMed  Google Scholar 

  23. Spitaels S, Arbogast C, Fouron JC, Davignon A (1974) The influence of heart rate and age on the systolic and diastolic time intervals in children. Circulation 49:1107–1115

    CAS  PubMed  Google Scholar 

  24. McAllister RG (1986) Kinetics and dynamics of nifedipine after oral and sublingual doses. Am J Med 81 [Suppl 6A]:2–5

  25. Van Harten J, Burggraaf K, Danhof M, Brummelen P van, Breimer DD (1987) Negligible sublingual absorption of nifedipine. Lancet II:1363–1365

    Google Scholar 

  26. Hatton RC, Marcadis ML (1988) Sublingual nifedipine in acute severe hypertension. Arch Dis Child 64:633

    Google Scholar 

  27. Stopfkuchen H, Schranz D, Ziegler R, Jungst BK (1985) Experiences with nifedipine in the treatment of acute hypertension in children. Monatsschr Kinderheilkd 133:242–246

    Google Scholar 

  28. Penza R, Francioso G, Lorusso L, D’Aloisio L, Aceto G, Acquafredda A, Cavallo L, Amendola F (1985) Nifedipine in hypertensive emergencies in children. Pediatr Med Chir 7:243–246

    PubMed  Google Scholar 

  29. Blaszak RT, Savage JA, Ellis E (2001) The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 139:34–37

    CAS  PubMed  Google Scholar 

  30. Lopez-Herce J, Albajara L, Cagigas P, Garcia S, Ruza F (1988) Treatment of hypertensive crisis in children with nifedipine. Intensive Care Med 14:519–521

    CAS  PubMed  Google Scholar 

  31. Sasaki R, Hiroto K, Masuda A (1997) Nifedipine-induced transient cerebral ischemia in a child with Cockayne syndrome. Anesthesia 52:1236

    CAS  Google Scholar 

  32. Ferlinz J (1986) Nifedipine in myocardial ischemia, systemic hypertension, and other cardiovascular disorders. Ann Intern Med 105:914–923

    Google Scholar 

  33. Floras JS (1988) Antihypertensive treatment, myocardial infarction, and nocturnal myocardial ischemia. Lancet II:994–996

    Article  Google Scholar 

  34. Phillips RA, Goldman ME, Ardeljan M, Eison HB, Shimabukuro S, Krakoff LR (1991) Isolated T wave abnormalities and evaluation of left ventricular wall motion after nifedipine for severe hypertension. Am J Hypertens 4:432–437

    CAS  PubMed  Google Scholar 

  35. Baumgart D, Ehring T, Heusch G (1993) A proischemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole. Cardiovasc Res 27:1254–1259

    CAS  PubMed  Google Scholar 

  36. Jariwalla AG, Anderson EG (1978) Production of ischemic cardiac pain by nifedipine. BMJ 1:1181–1182

    CAS  PubMed  Google Scholar 

  37. Waters D (1991) Proischemic complications of dihydropyridine calcium channel blockers. Circulation 84:2598–2600

    CAS  PubMed  Google Scholar 

  38. Lubbe WWF, Podzuweit T, Opie LH (1992) Potential arrhythmogenic role of cyclic AMP and cytosolic calcium overload: implications for antiarrhythmic effects of ß-blockers and pro-arrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 19:1622–1633

    CAS  PubMed  Google Scholar 

  39. Ferguson JJ, Momomura S (1994) Highlights from the 58th Annual Scientific Meeting of the Japanese Circulation Society. Circulation 90:2194–2196

    Google Scholar 

  40. Bachmann H (1982) Hypertension, a frequent complication in children and adolescents with reflux nephropathy. Klin Padiatr 194:152–153

    CAS  PubMed  Google Scholar 

  41. Ingelfinger JR (1992) Hypertension. In: Edelman CM (ed) Pediatric kidney disease, 2nd edn. Little Brown, Boston, pp 1889–1908

  42. Donnelly WH (1987) Ischemic myocardial necrosis and papillary muscle dysfunction in infants and children. Am J Cardiovasc Pathol 1:173–188

    CAS  PubMed  Google Scholar 

  43. Vardi P, Markiewicz W, Levy J, Adler O, Riss E, Benderley A (1979) The heart in acute glomerulonephritis: an echocardiographic study. Pediatrics 63:782–787

    CAS  PubMed  Google Scholar 

  44. Christensen ML, Helms RA, Chesney RW (1999) Is pediatric labeling really necessary? Pediatrics 104:593–597

    CAS  PubMed  Google Scholar 

  45. 21 Code of Federal Regulation (CFR) 201.57 (f) (9)

Download references

Acknowledgement

This study was supported by a research grant from the Children’s Hospital of Eastern Ontario Research Institute.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Alberta, Edmonton, Alberta, T6G 2R7, Canada

    Verna Yiu, Rhonda J. Rosychuk, Manjula Gowrishankar & Frances Harley

  2. Department of Pediatrics, University of Ottawa, Ottawa, Canada

    Elaine Orrbine, Peter MacLaine & Guido Filler

  3. Department of Pediatrics, McGill University, Canada

    Paul Goodyer & Colette Girardin

  4. Department of Pediatrics, University of Manitoba, Canada

    Malcolm Ogborn

  5. Department of Pediatrics, University of Calgary, Canada

    Julian Midgley

Authors
  1. Verna Yiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elaine Orrbine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rhonda J. Rosychuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter MacLaine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Goodyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Colette Girardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manjula Gowrishankar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Malcolm Ogborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Julian Midgley
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guido Filler
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Frances Harley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Verna Yiu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yiu, V., Orrbine, E., Rosychuk, R.J. et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 19, 644–650 (2004). https://doi.org/10.1007/s00467-004-1444-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1444-x

Keywords

Search

Navigation